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Abstract
Programmed death-1 (PD-1) is an immunoreceptor predominantly expressed on exhausted T cells, which through an
interaction with its ligand (PD-L1), controls peripheral tolerance by limiting effector functions of T lymphocytes. qRT-PCR for
PD-1, PD-L1 and their splicing forms as well as flow cytometric assessment of surface expression was performed in a cohort
of 58 chronic lymphocytic leukemia (CLL) patients. In functional studies, we assessed the influence of the proliferative
response of leukemic B-cells induced by IL-4 and CD40L on PD-1 transcripts and expression on the protein level. The median
level of PD-1, but not PD-L1, transcripts in CLL patients was higher in comparison to healthy volunteers (HVs, n=43,
p=0.0057). We confirmed the presence of PD-1 and PD-L1 on the CLL cell surface, and found the expression of PD-1, but
not PD-L1, to be higher among CLL patients in comparison to HVs (47.2% vs. 14.8%, p,0.0001). The Kaplan-Meier curves for
the time to progression and overall survival in groups with high and low surface expression of PD-1 and PD-L1 revealed no
prognostic value in CLL patients. After stimulation with IL-4 and CD40L, protein expression of PD-1 was significantly
increased in samples that responded and up-regulated CD38. PD-1, which is aberrantly expressed both at mRNA and cell
surface levels in CLL cells might represent a novel immunotolerant molecule involved in the pathomechanism of the
disease, and could provide a novel target for future therapies.
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Introduction
Chronic lymphocytic leukemia (CLL) is the most common adult
leukemia in the western population and it is characterized by a
heterogeneous clinical course [1]. Mechanisms of CLL pathogen-
esis are not fully described yet. However, there is growing evidence
for the involvement of external microenviromental and internal
genetic and epigenetic alternations [1]. Emerging data underlines
the key role of the B-cell receptor (BCR) in CLL transformation
and progression [1]. Functional BCRs are responsible for antigen-
mediated stimulation of both normal and malignant B cells.
However, in CLL cells the BCR is weakly expressed [1,2]. It is
noteworthy that several factors involved in BCR signaling have
impact on the biology and prognosis of CLL. In the leukemic cells,
an aberrant expression of 70 kDa tyrosine kinase zeta-associated
protein (ZAP-70), which takes part in the BCR signal transduction
pathway, correlates with poor prognosis [3]. Presence of an
unmutated gene of the variable regions of the immunoglobulin
heavy chain (IGHV) appears in about half of CLL patients and is
correlated with an unfavorable prognosis [4]. Additionally, over
20% of leukemic cells are carrying stereotyped BCRs, which might
suggest a role for antigenic drive in CLL pathogenesis [5].
Stereotyped receptors are more frequent in CLL cell with
unmutated IGHV genes [6].
Programmed death-1 (PD-1, CD279), a member of the CD28
receptor family, is expressed temporally on T and B lymphocytes
upon their activation and binds programmed death ligand-1 (PD-
L1, B7-H1, CD274) and PD-L2 (B7-DC, CD273). Interactions of
PD-1 with PD-L1 and PD-L2 are well described for T cells, where
they inhibit proliferation, cytokine production and cytotoxic
capabilities, characterizing thereby ‘‘exhausted’’ T cells [7,8].
PD-1, attenuates T cells response and thereby plays a role in
maintenance of peripheral tolerance [9]. The function of this
receptor on tumor cells is unknown. However, up-regulated PD-
L1 expression was described in several human tumors types,
including hematological malignancies [9,10,11,12]. In T cells, PD-
1 inhibits the transduction of T-cell receptor (TCR) signal by
blocking ZAP-70 phosphorylation and preventing phosphatidyli-
nositol 3-kinase (PI3K) activation by CD28, which inhibits
functions of AKT and extracellular signal-regulated kinase
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35178(ERK) [13,14]. The interaction between PD-L1 and PD-1 leads to
deactivation of molecules involved in BCR signal transduction
pathway including Syk, PLCc, ERK1/2, B-cell linker protein
(BLNK) and PI3K as well as it is blocking activation of ZAP-70 in
T cells [15].
PD-1 is expressed on activated lymphocytes and up-regulated
upon their stimulation [16]. Since i) the phenotype of CLL cells
has several features characteristic for activated, antigen experi-
enced B cells, ii) PD-1 expression is present in microenvironment
of other B-cell malignancies, iii) CLL has some features of T-cells
including ZAP-70, CD-5 and CD38, characterization of PD-1 and
PD-L1 expression might give deeper insight into CLL biology
[17].
Results
Differential mRNA expression of PD-1, Dexon2,3,4 PD-1
and Dexon2 PD-L1 splicing variants in CLL patients
For 32 patients samples isolated from PBMCs and cells isolated
from BM of 11 patients were analyzed using qRT-PCR. In further
analyzes, the tissue source of the analyzed cells showed no
significant differences, and therefore in subsequent experiments
samples were analyzed collectively.
The organization of PD-1 and PD-L1 splicing variants is
presented in Figure 1. The level of full length (fl_PD-1) transcript
of PD-1 was elevated in CLL patients in comparison to HVs, with
a median relative fl_PD-1/GAPDH expression of 0.57 vs. 0.12,
p=0.0057 (Table 1). The levels of mRNAs splicing variants
lacking of exon 2 (Dex2_PD-1), exon 3 (Dex3_PD-1) and both
exons (Dex2,3_PD-1) showed no significant differences between
HVs and CLL samples. Expression of PD-1 transcripts lacking
exons 2, 3 and 4 (Dex2,3,4_PD-1) was higher in HVs than in CLL
patients (p=0.0465). No difference in the expression of the full
length PD-L1 (fl_PD-L1) splicing variant was observed between
the two analyzed groups. However, the PD-L1 splicing variant
lacking exon 2 (Dex2_PD-L1) was highly expressed in CLL
patients in comparison to HVs. Exemplary amplification and
dissociation curves for PD-1 and PD-L1 slicing variants are
displayed in Figure S1.
Expression of PD-1 and PD-L1 do not correlate with
clinical parameters of CLL patients
To further characterize PD-1 and PD-L1 expression, we
correlated their expression with clinical parameters of CLL
patients. There was no correlation between fl_PD-1 and fl_PD-
L1 expression and sex, age, disease stage according to the Binet
staging system, cytogenetic abnormalities, expression of ZAP-70
and CD38, percentages of regulatory T lymphocytes and level of
lactate dehydrogenase.
We analyzed Kaplan-Meier curves for the time to progression
(TTP) and overall survival (OS) in groups with high and low
expression levels of PD-1 and PD-L1. Neither PD-1 nor PD-L1
expression level has prognostic value for either TTP or OS.
Expression PD-1 and PD-L1 on CLL cells
To confirm protein expression of PD-1 on CD5
+CD19
+ cells
isolated from 45 CLL patients, flow cytometry analysis was
performed and revealed the presence of PD-1 molecules in all
samples. The expression of PD-1 on CD5
+CD19
+ was higher as
compared to expression on healthy B cells (47.2% vs. 14.81%,
p,0.0001, Figure 2A). The representative plot of the flow
cytometric analysis of PD-1 expression is presented in Figure S2.




was comparable to percentages observed on CD19
+ B cell of
healthy control (Figure S2E). Next, the median of the mean
fluorescence intensity (MFI) of the PD-1 molecules on CLL cells
and HVs was measured to reflect expression levels. Median MFI of
PD-1 tended to be higher on CLL cells than on CD19
+ cells of
Figure 1. Schematic representation of the organization of PD-1 (A) and PD-L1 (B) splicing variants. Primer localization is marked with
arrows. Primers were designed to anneal at exon junctions that are specific for the particular splicing variant.
doi:10.1371/journal.pone.0035178.g001
Table 1. Median expression of PD-1 and PD-L1 splicing
variants.
Splicing variant CLL patients HVs Statistical significance
fl_PD-1 0.5699 0.117 Yes (p=0.0057)
Dex2_PD-1 0.1287 0.1208 No
Dex3_PD-1 0.1748 0.135 No
Dex2,3_PD-1 0.1018 0.06951 No
Dex2,3,4_PD-1 0.1027 0.1993 Yes (p=0.0465)
fl_PD-L1 0.4297 0.2648 No
Dex2_PD-L1 0.3571 20.2649 Yes (p=0.0085)
The expression levels of PD-1, PD-L1 and their splicing variants were calculated
as an inverse ratio of the difference in cycle threshold (DCt) method, where DCt
is the Ct value of the target splicing variant minus the Ct value of GAPDH.
doi:10.1371/journal.pone.0035178.t001
PD-1 in CLL
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Figure 2B)
We also assessed surface expression of PD-L1 on CLL cells from
44 patients and 10 HVs using flow cytometry. Expression of PD-
L1 was observed in all samples at similar levels (median: 52.52%,
range 10.8%–97.3%, p=0.22, Figure 2C). The representative plot
of the flow cytometric analysis of PD-L1 expression is presented in
Figure S2. Interestingly, the MFI values of PD-L1 reflecting the
expression levels on CLL cells were higher when compared to
HVs (9.96 vs. 7.93, p=0.017, Figure 2D). The MFI of PD-1 and
PD-L1 on CLL cells showed a positive correlation (r
2=0.34,
p,0.05, Figure 2E).
Association of PD-1 and PD-L1 protein expression on CLL
cells with clinical parameters of CLL patients
Surface expression PD-1 and its ligand were analyzed with
relation to age, sex and stage of disease. No correlation between
expression of PD-1 nor PD-L1 and sex, age or a stage of disease
was found. There was also no difference of expression of PD-1
Figure 2. Surface expression of PD-1 and PD-L1 on cells from CLL patients and HVs. Figure displays a flow cytometric analysis of PD-1 and
PD-L1 expression on CLL cells and normal B cells. (A) Median PD-1 expression of PD-1 on CD5
+CD19
+ CLL cells and control B cells of healthy
volunteers (HVs) (47.2% vs. 14.81%, p,0.0001). (B) The mean fluorescence intensity MFI of PD-1 on CD5
+CD19
+ CLL cells and control B cells of HVs
(12.49 vs. 8.59, respectively, p=0.078). (C) Median PD-L1 expression on CD5
+CD19
+ CLL cells and control B cells of HVs (median: 52.52%, range 10.8%–
97.3%, p=0.22). (D) PD-L1 MFI of CD5
+CD19
+ CLL cells and control B cells of HVs (9.96 vs. 7.93, p=0.017). (E) Correlation of MFI of PD-1 positive CLL
cells with PD-L1 positive CLL cells (r
2=0.34, p,0.05). MFI of PD-1 and PD-L1 on CD5
+CD19
+ leukemic cells and on CD19
+ control B cells was defined
by flow cytometric analysis (see Figure S2).
doi:10.1371/journal.pone.0035178.g002
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including ZAP-70 and CD38 as well as in different cytogenetic
subgroups as defined using the hierarchical model [18]. Interest-
ingly, the expression of PD-L1 was higher in ZAP-70-positive
patients (ZAP-70$20%) as compared to ZAP-70-negative (ZAP-
70,20%) cases (58.13% vs. 34.61%, p=0.0019). We also
observed no correlation between PD-1 and PD-L1 expression
and the percentages of regulatory T lymphocytes and the level of
lactate dehydrogenase.
The Kaplan-Meier curves for the TTP and OS in groups with
high and low surface expression of PD-1 and PD-L1 revealed no
prognostic value in CLL patients.
PD-1 expression after stimulation of CLL cells and normal
B cells with IL-4 and CD40L
Since our results showed elevated PD-1 expression on CLL
cells, in functional studies we characterized its expression after
stimulation with IL-4 and CD40L. There were no significant
difference between stimulated and non-stimulated CLL cells
neither on the PD-1 transcript level (1/DCt of 0.22 vs. 0.24,
respectively, p=0.54, Figure 3A) nor surface protein presence
(MFI PD-1, 82.22 vs. 69.34, p=0.48, Figure 3B). In HVs samples,
MFI of normal B cells after stimulation was not markedly elevated
in comparison to non-stimulated cells (206.5 vs. 212.7, p=0.59,
see Figure S3A)
For further characterization of PD-1 expression after stimula-
tion, we subsequently analyzed CD38 expression, which reflects
CLL cells proliferative potential [17]. PD-1 expression was
compared in groups of CLL patients and HVs with an up- or
down- regulation of CD38 upon stimulation. Levels of CD38 in
stimulated cells were compared to non-stimulated control. While
there was no differences in PD-1 mRNA levels in CLL cells in
both groups (2
2DDCt of 0.637 vs. 0.326, p=0.34, Figure 3C), the
DMFI of PD-1 was higher in the group who up-regulated CD38
after stimulation (DMFI of 6.240 vs. 26.670, p=0.0093,
Figure 3D). The DMFI of PD-1 of HVs samples up-regulating
CD38 after stimulation was not significantly different than those
with down-regulated CD38 (29.17 vs. 236.77, p=0.33, see Figure
S3B).
Discussion
Programmed death-1 (PD-1) was identified as an inducible
molecule on activated T cells, B cells, natural killer T cells,
macrophages and dendritic cells [7,12,16]. Through an interaction
with its ligand (PD-L1), PD-1 controls peripheral tolerance by
limiting activation, development and effector functions of T
lymphocytes. Expression of PD-1 and its ligand in hematological
malignances is still not well described on B cells. Expression of PD-
1 was found on tumor infiltrating and peripheral T cells in
Hodgkin lymphoma, B-cell non-Hodgkin lymphoma as well as in
the adult T-cell leukemia [19,20,21,22]. PD-1 was described also
as a marker of T cells associated with germinal centers and as a
marker of angioimmunoblastic T-cell lymphoma [19,23,24].
Among B-cell non-Hodgkin lymphomas, PD-1 presence was
described on 3 of 98 cases of diffuse large B-cell lymphomas
(DLBCL), 12 of 13 cases of small lymphocytic lymphoma and 10
of 11 cases of CLL [23,24]. In our study, we analyzed PD-1
expression on the surface of double positive CD5
+CD19
+ cells. We
found higher expression of PD-1 both on RNA and protein level in
CLL cells when compared to control B cells. Moreover, as a novel
feature of CLL cells we observed expression of PD-L1, which has
not been described in B-cell non-Hodgkin lymphomas to date
[22,24,25,26]. Notably, MFI of PD-L1 was higher on CLL cells
than on HVs B-cells, but the level of the full length PD-L1
transcript did not differ between those groups. Correlation of the
Figure 3. PD-1 expression after CLL cells stimulation with CD40L and IL-4. Figure displays analysis of PD-1 expression on both transcript
and protein levels on CLL cells after stimulation with CD40L and IL-4. (A) PD-1 mRNA expression level in stimulated cells and non-stimulated control
(0.22 vs. 0.24, p=0.54). (B) PD-1 MFI in stimulated and non-stimulated cells (82.22 vs. 69.34, p=0.48). (C) Difference of PD-1 mRNA expression levels
between stimulated cells and non-stimulated control assessed using qRT-PCR (2
2DDCt) and correlated with CD38 MFI, with samples segregated into
up-regulation or down-regulation of CD38 upon stimulation (0.637 vs. 0.326; p=0.34). (D) Change of PD-1 MFI between stimulated and non-
stimulated cells, with patients segregated as in (C) (6.240 vs. 26.670, p=0.0093).
doi:10.1371/journal.pone.0035178.g003
PD-1 in CLL
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indicate simultaneous activation of the signaling pathway of PD-1/
PD-L1, which could be a potential mechanism for tumor escape
from immunosurveillance.
In order to quantify the expression of PD-1 and PD-L1, we
examined alternative isoforms: 5 isoforms of PD-1 and 2 of PD-L1.
Dexon2_PD-1 and Dexon2_PD-L1 splicing variants are function-
ally disabled, since an exon 2 encodes an extracellular IgV-like
domain in both cases [27,28]. We found Dexon2_PD-L1 mRNA
to be transcribed with the significantly greater rate in CLL patients
than in cells from HVs. Lack of a transmembrane domain encoded
by an exon 3 leads to translation of a soluble form of the PD-1
protein (Dexon3_PD-1 transcript). In rheumatoid arthritis,
presence of a soluble PD-1 isoform in serum was linked with
disease activity characterized by rheumatoid factor in serum and
TNF in synovial fluid levels [29]. The Dexon2,3,4_PD-1 transcript
has a frame shift caused by alternative splicing that generates a
premature stop codon in exon 5 and results in a truncated form of
a protein if translated. Interestingly, we found a transcript of
Dexon2,3,4_PD-1 to be significantly elevated in cells from HVs in
comparison to CLL patients, despite the lack of an obvious
biological function of this isoform since exon 4 encodes a
cytoplasmatic signaling domain [30].
PD-1 is expressed on T cells and B cells upon their activation,
and mRNA levels of all splicing variants are increased in
stimulated T cells from HVs [16,27]. The phenotype of CLL
cells reveals multiple features characteristic of antigen-experi-
enced, activated B lymphocytes, that utilize extensively BCR
signaling-related molecules including aberrantly expressed ZAP-70
and CD38 [17,31,32]. Our results show that surface PD-1 was
significantly up-regulated in cells that increased CD38 expression
after stimulation, which suggests that PD-1 could be a marker of
the activated phenotype of CLL cells. PD-1/PD-L1 is a negative
immune system regulator in response to chronic infection and
supposedly protects cancer cells. It acts by impairing T-cell
functions and their proliferation, and its overexpression on CLL
cells upon their stimulation might represent a negative feedback
loop in response to stimuli [33,34]. However, such a regulation in
vivo appears to be more complex since no general correlation
between CD38 and PD-1 expression was found in a larger cohort
of CLL patients.
Recently, in follicular lymphoma (FL) the percentage of T cells
expressing PD-1 was found to be of prognostic value [35].
However, others showed that PD-1-positive tumor infiltrating T
cells are a negative prognostic factor in FL [26]. In the current
study, high or low PD-1 expression on either protein or transcript
levels has not influence on OS nor on TTP in the group of CLL
patients examined here.
Expression of PD-L1 in non-hematological malignances was
described in several entities, where it correlated with poor
prognosis. Inhibition of the PD-1/PD-L1 pathway was found to
be a promising target as it improved the anti-tumor immunological
response [7,36]. In this study we therefore chose to quantify the
expression of PD1 in CLL cells. Interestingly, we found higher
percentages of PD-L1-positive cells in ZAP-70 positive CLL
samples, but analyzes of PD-L1 did not reveal any prognostic
value for OS or TTP. In a therapeutic perspective, inhibition of
the PD-1/PD-L1 pathway by anti-PD-1 and anti-PD-L1 antibod-
ies has been described as a successful method of improving the
anti-tumor response in multiple murine models of human B-cell
malignancies, including acute myeloid leukemia [10,13,37].
Regarding the reversible ‘‘exhaustion’’ of T cells by effective
PD-1 blockade during chronic viral infection [38], a phase I
clinical trial for single-dose humanized anti-PD-1 antibody in
cancer patients was initiated. Berger et al. [39] enrolled 17 patients
with different hematological malignancies. In this study, one
complete remission in a follicular lymphoma case and stable
diseases in both enrolled CLL cases was achieved. Our finding that
PD-1 expression is elevated on CLL cells indicates the possibility of
using it as a target for immunotherapy.
In summary, we characterized expression of PD-1 and PD-L1 in
a cohort of 58 CLL patients. In CLL cells, we demonstrated
increased PD-1 expression on both the transcript and the surface
protein levels in comparison to healthy donors. By stimulating
CLL cells in cell culture with IL-4 and CD40L, we showed PD-1
to be overrepresented in a group of samples that responded to
stimulation by up-regulating CD38. We conclude that both PD-1
and PD-L1 might represent novel features of the CLL cell




This study was approved by the Ethics Committee of the
Medical University of Lublin (No. KE-0254/150/2008). Written
informed consent was obtained from all patients with respect to
the use of their blood for scientific purposes.
Patients
Peripheral blood was collected from 58 CLL patients treated in
the Department of Hematooncology, Medical University of
Lublin, Poland, as well as from 20 age- and sex-matched healthy
volunteers (HVs). The clinical characteristics of the patients are
summarized in Table 2. For 43 patients assessment of mRNA
expression was performed with qRT-PCR. A group of 45 patients
was analyzed with flow cytometry, with thirty of them analyzed in
both groups.
Cell isolation
Mononuclear cells were isolated from peripheral blood (PBMC)
or bone marrow (BM) by Ficoll (Biochrom AG, Berlin, Germany)
density gradient centrifugation. The viability of obtained cells was
always .95% as determined by exclusion of trypan blue. Viable
cells were quantified in a Neubauer chamber (Zeiss, Oberkochen,
Germany) and stored for further analysis in liquid nitrogen. For
total RNA isolation, ten million cells were pelleted and stored in
280uC.
mRNA preparation and reverse transcription
For total RNA isolation from PBMCs QIAamp RNA Blood
Mini Kit (Qiagen, Venlo, Netherlands) was used according to the
manufacturer’s instructions. From each sample, 1 mg of total RNA
was reverse transcribed to 20 ml of cDNA using QuantiTect
Reverse Transcription Kit (Qiagen). For quantitative RT-PCR
reactions, 1 ml of cDNA of each sample was used.
Quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR)
For quantitative measurements of the mRNA expression of PD-
1, PD-L1 and their splicing variants, quantitative RT-PCR was
performed using FastStart Universal SYBR Green Master
methodology according to the manufacturer protocol (Roche
Diagnostics, Mannheim, Germany). Primers for PD-1 and
respective splicing variants (NM-005018) and for PD-L1 and a
splicing variant (NM-014143) are described in Table 3. As a
constitutively expressed housekeeping gene, glyceraldehyde-3-
PD-1 in CLL
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program was set for 40 cycles of 15 sec at 95uC, 1 min at 60uC
with an initial denaturation step at 95uC for 10 min on the ABI
Prism 7300 Sequence Detector (Applied Biosystems, Foster City,
CA, USA). Particular expression levels were calculated as an
inverse ratio of the difference in cycle threshold (DCt), where DCt
is the Ct value of the target splicing variant minus the Ct value of
GAPDH.
Flow cytometry
For the flow cytometric analysis of the surface expression of the
PD-1 and PD-L1, 45 CLL patients (group B, Table 2) were
additionally assessed. Initially, CD19 positive cells from PBMC
were separated in magnetic field according to the manufacturer’s
protocol (MACS Milltenyi Biotec, Bergisch Gladbach, Germany).
Next CD19 cells were stained with mAbs against surface antigens
for 15 minutes at room temperature in the dark. CLL cells were
identified in the live cell population using phycoerythrin cyanin 5
(PE-Cy5)-conjugated anti-CD5 mAb (BD Biosciences, Mannheim,
Germany). PD-1 and PD-L1 expression was examined using
fluorescein isothiocyanate (FITC)-conjugated anti-PD-1 mAb and
phycoerythrin (PE)-conjugated anti-PD-L1, respectively (eBios-
ciences, San Diego, USA). After staining, cells were washed and
analyzed by FACSCalibur (BD Biosciences). The results were
evaluated by Summit Software (Dako Cytomation, Glostrup,
Denmark).
Flow cytometric analysis of regulatory T lymphocytes




+ as described earlier in details [40].
Leukemic B cell stimulation with IL-4 and CD40L
For functional studies, CD19 positive cells from PBMC cells
from 21 CLL patients (median age: 65, sex: 9F, 12M) and from 11
HVs (median age: 58, sex: 6F, 5M) were separated in magnetic
field according to the manufacturers protocol (MACS Milltenyi
Biotec). Cells were cultured for 24 h in a standard medium
consisting RPMI-1640 (Biochrom, Berlin, Germany) supplement-
ed with 10% (v/v) FCS serum, 50 units/ml penicillin, 50 mg/ml
streptomycin and 100 mg/ml neomycin with and without addition
of 0.01 ng/ml IL-4 and 200 ng/ml CD40L.
After culture, cells were harvested and analyzed for PD-1
expression using qRT-PCR. The difference in PD-1 mRNA
expression between stimulated and non-stimulated cells of CLL
patients was calculated using the 2
2DDCt method, where DDCt
represents the difference in DCt of PD-1 between stimulated and
non-stimulated cells.
Subsequently, after cell culture, flow cytometry analysis was
used to assess CD38 expression, which reflects the proliferative
response of cells to the stimulation cocktail. In addition, the PD-1
surface expression on CD5
+CD19
+ CLL cells was measured for
CLL samples and on CD19
+ normal B cells for HVs samples. The
Table 2. Clinical characteristics of CLL patients of groups A
and B.
Characteristic Subcategory A B
Sex Female 15 16
Male 28 29






Binet Stage A1 7 2 3
B1 9 1 5
C7 7





Other karyotype 4 3
Not available 7 13
ZAP-70 (cut-off 20%) Positive 25 27
Negative 15 13
Not available 3 5
CD38 (cut-off 30%) Positive 8 9
Negative 32 31
Not available 3 5
A – the group of 43 patients analyzed by qRT-PCR for PD-1, PD-L1 and their
splicing variants.
B – the group of 45 patients analyzed by flow cytometry method.
Detailed characteristics of CLL patients are presented in Table S1.
doi:10.1371/journal.pone.0035178.t002
Table 3. Primer sequences.
Transcript name Primer sequences
fl_PD-1 F: 59-CTCAGGGTGACAGAGAGAAG-39 R: 59-GACACCAACCACCAGGGTTT-39
Dex2_PD-1 F: 59-GGTTCTTAGAGAGAAGGGCA-39 R: 59-GACACCAACCACCAGGGTTT-39
Dex3_PD-1 F: 59-AGGGTGACAGGGACAATAGG-39 R: 59-CCATAGTCCACAGAGAACAC-39
Dex2,3_PD-1 F: 59-TGGTTCTTAGGGACAATAGG-39 R: 59-TCTTCTCTCGCCACTGGAAA-39
Dex2,3,4_PD-1 F: 59-TGGTTCTTAGAAGGAGGACC-39 R: 59-TCTTCTCTCGCCACTGGAAA-39
fl_PD-L1 F: 59-TATGGTGGTGCCGACTACAA-39 R: 59- TGCTTGTCCAGATGACTTCG-39
Dex2_PD-L1 F: 59-ACGCCCCATACAACAAAATC-39 R: 59-CTCTTGGAATTGGTGGTGGT-39
F, forward; R, reverse; fl_PD-1, full length PD-1; Dex2_PD-1, PD-1 lacking exon 2; Dex3_PD-1; PD-1 lacking exon 3; Dex2,3_PD-1, PD-1 lacking exons 2 and 3; Dex2,3,4_PD-
1, PD-1 lacking exons 2, 3 and 4; fl_PD-L1, full length PD-L1; Dex2_PD-L1, PD-L1 lacking exon 2.
doi:10.1371/journal.pone.0035178.t003
PD-1 in CLL
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stimulated and non-stimulated cells was calculated as DMFI PD-1.
Statistical analysis
All results are presented as median values with range. The U
Mann–Whitney test was used to evaluate the differences between
subgroups of patients and the Wilcoxon signed-rank test for
comparing samples in the functional studies. Correlations of
variables were computed with the Spearman rank correlation
coefficient. The Kaplan–Meier method and the log-rank test were
used to assess time to progression (TTP) and overall survival (OS)
in different groups of patients.
Supporting Information
Figure S1 The amplification (left column) and dissoci-
ation curves (right column) for PD-1 and PD-L1 splicing
variants by qRT-PCR.
(TIF)
Figure S2 Five-parameter flow cytometric analysis of
PD-1 and PD-1L expression in chronic lymphocytic
leukemia and healthy volunteers. Figure displays a repre-
sentative plot of five-parameter flow cytometric analysis for PD-1
and PD-1L after CD19+ magnetic separation (as described in
details in methods section). Chronic lymphocytic leukemia (CLL)
cells were further gated as CD5 positive cells (A). As compared
with control (B) expression of PD-1 on CD5
+CD19
+ CLL was
measured (C). Other gating strategy on CD5
2CD19
+ (D) normal
B cells in CLL revealed percentages of PD-1+cells comparable
with those observed in healthy controls (E). Simultaneously
expression of PD-1L was measured on CLL cells (F).
(TIF)
Figure S3 PD-1 expression on B cells of healthy controls
after stimulation with CD40L and IL-4. Figure displays (A)
PD-1 MFI in stimulated and non-stimulated B cells of healthy
volunteers (HVs) (206.5 vs. 212.7, p=0.59). (B) The difference of
PD-1 MFI after stimulation in groups of cases who up-regulated or
down-regulated CD38 upon stimulation (29.17 vs. 236.77,
p=0.33).
(TIF)
Table S1 Clinical characteristics of CLL patients.
(DOC)
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